High Cure Rates Seen With Merck Oral Hepatitis Drugs: Study

A combination of two oral hepatitis C treatments developed by Merck led to high cure rates in previously untreated patients, indicating the company is a contender in the race to find new treatments for the liver destroying virus.
The Baltimore Sun